• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
YUAN Mingyang,ZHOU Xuegang,HU Dandan,JIANG Lei,YANG Bo,PENG Haisheng.Discussion on the mechanisms of couplet medicine of “Bupleuri Radix-Angelicae Sinensis Radix” for mammary gland hyperplasia based on network pharmacology and molecular docking[J].Journal Of Pharmaceutical Research,2022,41(2):71-78[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2675times   Download 2901次 QR Code for this article
Scan with your phone!
基于网络药理学及分子对接探讨“柴胡-当归”药对治疗乳腺增生的作用机制
袁名扬1,周学刚2,扈丹丹2,蒋蕾2,杨波1,彭海生2
Font:Larger+|Default|Smaller-
(1.哈尔滨商业大学药学院,黑龙江 哈尔滨 150076;2.哈尔滨医科大学大庆校区药学院,黑龙江 大庆 163319)
摘要:
目的 通过网络药理学和分子对接技术探索“柴胡-当归”药对治疗乳腺增生的潜在作用机制。方法 基于网络药理学,通过TCMSP、UniProt等数据库检索获得“柴胡-当归”药对的活性成分及其对应靶点蛋白。在Genecards数据库检索乳腺增生相关靶点,利用Draw Venn Diagram在线作图网站获得其与“柴胡-当归”作用靶点的交集基因。通过Cytoscape 3.6.0软件及STRING数据库构建药对-活性成分-作用靶点-疾病网络和靶点间蛋白-蛋白相互作用(PPI)网络,根据度值大小筛选出排名前5的靶蛋白,并利用RCSB PDB数据库、Autodock Vina 1.1.2等软件预测其与“柴胡-当归”药对活性成分的结合活性。采用RStudio软件对交集基因进行GO富集分析和KEGG通路富集分析,最终构建活性成分-关键靶点-关键通路网络。结果 数据库中筛选获得药对活性成分共18种;其中活性成分的靶点与乳腺增生疾病的交集基因共150个,根据度值排名大小获得5个核心靶标,包括蛋白激酶、白细胞介素-6、肿瘤蛋白p53、血管内皮生长因子A及肿瘤坏死因子等。经分子对接分析发现,“柴胡-当归”药对的活性成分与核心靶标结合能力较强。结论 “柴胡-当归”药对的主要活性成分可能通过调节蛋白激酶、白细胞介素-6、肿瘤蛋白p53、血管内皮生长因子A及肿瘤坏死因子等核心靶点,参与调控白介素-7(IL-7)信号通路、内分泌耐药、丝裂原活化蛋白激酶(MAPK)信号通路、肿瘤坏死因子(TNF)信号通路、缺氧诱导因子1(HIF-1)信号通路等途径,发挥对乳腺增生的治疗作用。
关键词:  “柴胡-当归”药对  网络药理  分子对接  乳腺增生  作用机制
DOI:
基金项目:黑龙江省中医药管理局项目(No.ZHY18-153);黑龙江省中医药管理局项目(No.ZHY18-151);黑龙江省自然科学基金联合引导项目(No.LH2019H011)
Discussion on the mechanisms of couplet medicine of “Bupleuri Radix-Angelicae Sinensis Radix” for mammary gland hyperplasia based on network pharmacology and molecular docking
YUAN Mingyang1,ZHOU Xuegang2,HU Dandan2,JIANG Lei2,YANG Bo1,PENG Haisheng2
(1.Department of Pharmacy, Harbin University of Commerce, Harbin 150076, China; 2.Department of Pharmacy, Daqing Campus, Harbin Medical University, Daqing 163319,China)
Abstract:
Objective To explore the potential mechanism of couplet medicine of “Bupleuri Radix-Angelicae Sinensis Radix” for mammary gland hyperplasia through network pharmacology and molecular docking.Methods All the active ingredients and targets of couplet medicine of “Bupleuri Radix-Angelicae Sinensis Radix” were screened out based on the databases like TCMSP and UniProt. The disease targets in Mammary gland hyperplasia were retrieved by the Genecards database, then the intersection genes of obove targets with “Bupleuri Radix-Angelicae Sinensis Radix” targets were obtained by the Draw Venn Diagram online mapping website. Cytoscape 3.6.0 software and String database were applied for the construction of the couplet medicine-active components-targets-disease network map and target protein interaction network. The top 5 target proteins were screened according to the degree value, then the binding activity of its affinity with active components were predicted by RCSB PDB database and Autodock Vina 1.1.2 software. GO biological process enrichment and KEGG signal pathway analysis were carried out on the targets with the help of RStudio software. Finally, a network of active components-key target-key pathway was constructed. Results A total of 18 active ingredients and 150 intersection genes were obtained from the interaction between ingredient targets and mammary gland hyperplasia diseases targets. Five core targets were obtained according to the rank of degree values, which includes AKT1, IL-6, TP53, VEGFA, and TNF. The results of molecular docking proved that the main active components had great degree of affinity with core targets. Results of GO bioprocess analysis showed that the role of couplet medicine of “Bupleuri Radix-Angelicae Sinensis Radix” in the treatment of MGH was related to oxygen species metabolic process, cellular response to oxidative stress, cytokine receptor binding and transcription cofactor binding, etc. KEGG pathway enrichment analysis showed that the couplet medicine could play a therapeutic role by IL-17 signaling pathway and TNF signaling pathway, etc.Conclusion The main active components of couplet medicine of “Bupleuri Radix-Angelicae Sinensis Radix” may play a role in the treatment of mammary hyperplasia by regulating AKT1, IL-6, TP53, VEGFA, TNF and participating in IL-17 signaling pathway, Endocrine resistance, MAPK signaling pathway, TNF signaling pathway, HIF-1 signaling pathway.
Key words:  Couplet medicine of “Bupleuri Radix-Angelicae Sinensis Radix”  Network pharmacology  Mammary gland hyperplasia  Molecular docking  Mechanism
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.